Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

NextEdge Admin

15 Nov 2024

2 min 23 sec

OptraSCAN,Digital Pathology,AI solutions

Molbio Diagnostics, a leading molecular diagnostics company, has announced a $30 million investment in OptraSCAN, a San Jose-based digital pathology innovator. This strategic partnership aims to enhance global access to cutting-edge digital pathology solutions powered by artificial intelligence. The collaboration will focus on cloud-based systems for slide scanning, image analysis, and secure data storage, enabling faster and more accurate diagnoses for healthcare providers worldwide.

Sriram Natarajan, CEO of Molbio Diagnostics, emphasized the shared vision, stating, “At Molbio Diagnostics, we believe timely and accurate diagnostics should be a right, not a privilege. Partnering with OptraSCAN marks a vital step toward our goal of making high-quality, affordable healthcare accessible globally. Together, we are bringing innovative digital pathology solutions to India and beyond, empowering clinicians to improve patient care.”

OptraSCAN’s solutions cater to diverse healthcare settings, from small labs to large medical facilities. With Molbio’s support, the company plans to expand its product range and extend the reach of advanced diagnostic tools to underserved regions, particularly in rural India.

Abhi Gholap, Founder and CEO of OptraSCAN, shared, “This partnership allows us to deliver life-saving digital pathology solutions to a broader market. Together, we aim to bridge gaps in healthcare by providing timely, precise diagnoses to laboratories of all sizes.”

The alliance will also drive the development of AI-powered pathology tools, enhancing diagnostic efficiency. This investment will strengthen OptraSCAN’s R&D, expand its global footprint, and make advanced diagnostics more accessible in under-resourced areas.